www.skyrizi.com Open in urlscan Pro
2600:9000:2127:600:5:8ced:94c0:93a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Learn how AbbVie could help you save on SKYRIZI.
Call 1.866.SKYRIZI or click tap to learn more ▸

Skip to Main content
 * Important Safety Information
 * Full Prescribing Information & Patient Information
    * Full Prescribing Information (English)
    * Medication Guide

 * Healthcare Professionals Site

For Adults with Moderate to Severe Crohn’s Disease
Cost & Savings
 * Cost & Savings
 * Sign in or Register

 * 
 * Logout
 * test



 * SKYRIZI
 * Change Condition
    * Moderate to Severe Plaque Psoriasis
    * Active Psoriatic Arthritis
    * Moderate to Severe Crohn's Disease

 * Crohn’s Disease
    * What is Crohn's Disease?

 * About SKYRIZI
    * What Is SKYRIZI?
    * How SKYRIZI Works
    * SKYRIZI Dosing
    * SKYRIZI Side Effects

 * SKYRIZI Results
    * SKYRIZI Results

 * Asking About SKYRIZI
    * Prepare for Your Appointment
    * Find a Gastro

 * Starting SKYRIZI
    * About Skyrizi Complete
    * Ways to Save
    * Your Nurse Ambassador
    * Infusion Support
    * On-Body Injector Support
    * Resources to Stay on Track

 * Managing Your Treatment
    * Understanding Insurance
    * Share Your Story

 * Sign In or Register
 * Cost & Savings

First IL-23i that can

DELIVER CLINICAL

REMISSION

&

VISIBLY

IMPROVE DAMAGE

OF THE INTESTINAL LINING

At 12 and 52 Weeks

See SKYRIZI Results


 


WHAT IS SKYRIZI?

Get Answers

 


RESULTS WITH SKYRIZI

See the Data

 


HOW TO TAKE SKYRIZI

Get Dosing Details

 


SAVE WITH COMPLETE

Learn About Support



TAKE CONTROL OF YOUR CROHN'S WITH SKYRIZI

Learn how SKYRIZI helps people with Crohn's achieve significant symptom relief
at 4 weeks, including less abdominal pain and fewer bowel movements,
long-lasting remission at 1 year, and visibly improve damage of the intestinal
lining.

See the Results


ONLY 6 DOSES A YEAR

After 3 Starter Doses

Make SKYRIZI part of your routine with at-home dosing every 8 weeks, after a
total of 3 starter doses through a vein in the arm (intravenous infusion) and
proper training from your healthcare professional.

Find Out More About Dosing

endoscopic improvement

At least a 50% visible improvement of the intestinal lining.


LOOKING FOR UPDATES, ANSWERS, AND SKYRIZI SUPPORT?

Get more information and resources sent directly to you.

Sign Up


YOUR DEDICATED NURSE AMBASSADOR*

Your Skyrizi Complete Nurse Ambassador is committed to getting to know you and
your individual SKYRIZI needs.

Get to Know the Nurse Ambassador

*Nurse Ambassadors are provided by AbbVie and do not work under the direction of
your health care professional (HCP) or give medical advice. They are trained to
direct patients to their HCP for treatment-related advice, including further
referrals.


HELP US GUIDE YOU

What’s most important to you when looking for a Crohn’s treatment?

Symptom relief Its safety profile How it works


SYMPTOM RELIEF

Did you know that in clinical studies, SKYRIZI helped patients achieve symptom
relief in as early as 4 weeks?
Click below to learn more about SKYRIZI.

See SKYRIZI Results


ITS SAFETY PROFILE

Ask your doctor about the benefits and risks of SKYRIZI.
Before making a decision, get the facts.

See SKYRIZI Side Effects


HOW IT WORKS

SKYRIZI is a treatment that works differently by specifically targeting the
IL-23 protein, which is one of the key proteins responsible for inflammation. By
targeting IL-23, SKYRIZI helps reduce the excess inflammation that can
contribute to Crohn’s symptoms.

See How SKYRIZI Works


SHARE YOUR SKYRIZI STORY

Already taking SKYRIZI? Share your experience with SKYRIZI to help inform and
inspire others. To participate, please email us at info@SPEAKnetwork.net or call
888-298-8269.

--------------------------------------------------------------------------------


DOWNLOAD OUR PATIENT BROCHURE

This patient brochure can help answer questions you may have about Crohn's and
how SKYRIZI can help.

Download the Brochure



USE

SKYRIZI is a prescription medicine used to treat moderate to severe Crohn's
disease in adults.


IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT SKYRIZI®
(RISANKIZUMAB-RZAA)?

SKYRIZI IS A PRESCRIPTION MEDICINE THAT MAY CAUSE SERIOUS SIDE EFFECTS,
INCLUDING:

SERIOUS ALLERGIC REACTIONS:

 * Stop using SKYRIZI and get emergency medical help right away if you get any
   of the following symptoms of a serious allergic reaction:
   * - fainting, dizziness, feeling lightheaded
     (low blood pressure)
   * - swelling of your face, eyelids, lips, mouth,
     tongue, or throat
   * - trouble breathing or throat tightness
   * - chest tightness
   * - skin rash, hives
   * - itching

INFECTIONS:

SKYRIZI may lower the ability of your immune system to fight infections and may
increase your risk of infections. Your healthcare provider should check you for
infections and tuberculosis (TB) before starting treatment with SKYRIZI and may
treat you for TB before you begin treatment with SKYRIZI if you have a history
of TB or have active TB. Your healthcare provider should watch you closely for
signs and symptoms of TB during and after treatment with SKYRIZI.

 * Tell your healthcare provider right away if you have an infection or have
   symptoms of an infection, including:
   * - fever, sweats, or chills
   * - cough
   * - shortness of breath
   * - blood in your mucus (phlegm)
   * - muscle aches
   * - warm, red, or painful skin
     or sores on your body different from your psoriasis
   * - weight loss
   * - diarrhea or stomach pain
   * - burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the
ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a
complete list of ingredients.

BEFORE USING SKYRIZI, TELL YOUR HEALTHCARE PROVIDER ABOUT ALL OF YOUR MEDICAL
CONDITIONS, INCLUDING IF YOU:

 * have any of the conditions or symptoms listed in the section "What is the
   most important information I should know about SKYRIZI?"
 * have an infection that does not go away or that keeps coming back.
 * have TB or have been in close contact with someone with TB.
 * have recently received or are scheduled to receive an immunization (vaccine).
   Medicines that interact with the immune system may increase your risk of
   getting an infection after receiving live vaccines. You should avoid
   receiving live vaccines right before, during, or right after treatment with
   SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before
   receiving a vaccine.
 * are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm
   your unborn baby.
 * are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes
   into your breast milk.
 * become pregnant while taking SKYRIZI. You are encouraged to enroll in the
   Pregnancy Registry, which is used to collect information about the health of
   you and your baby. Talk with your healthcare provider or call 1-877-302-2161
   to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important
information I should know about SKYRIZI?"

Liver problems in Crohn's disease: A person with Crohn's disease who received
SKYRIZI through a vein in the arm developed changes in liver blood tests with a
rash that led to hospitalization. Your healthcare provider will do blood tests
to check your liver before, during, and up to 12 weeks of treatment and may stop
treatment with SKYRIZI if you develop liver problems. Tell your healthcare
provider right away if you notice any of the following symptoms: unexplained
rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of
appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn’s disease
include: upper respiratory infections, headache, joint pain, stomach (abdominal)
pain, injection site reactions, low red blood cells (anemia), fever, back pain,
and urinary tract infection.

The most common side effects of SKYRIZI in people treated for plaque psoriasis
and psoriatic arthritis include: upper respiratory infections, headache, feeling
tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for
medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL
vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose
prefilled cartridge with on-body injector.

USES

SKYRIZI is a prescription medicine used to treat adults with:

 * moderate to severe plaque psoriasis who may benefit from taking injections or
   pills (systemic therapy) or treatment using ultraviolet or UV light
   (phototherapy).
 * active psoriatic arthritis (PsA).
 * moderate to severe Crohn's disease.

US-SKZ-220579

Please see the Full Prescribing Information, including the Medication Guide, for
SKYRIZI.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to
help.
Visit AbbVie.com/myAbbVieAssist to learn more.

Legal Notices/Privacy Policy. Copyright 2023, AbbVie Inc., North Chicago,
Illinois, U.S.A. If you have any questions about AbbVie’s SKYRIZI.com website
that have not been answered, click here. This website and the information
contained herein is intended for use by US residents only, is provided for
informational purposes only and is not intended to replace a discussion with a
healthcare provider. All decisions regarding patient care must be made with a
healthcare provider and consider the unique characteristics of each patient.

SKYRIZI (RISANKIZUMAB-RZAA)

 * Moderate to Severe Crohn's Disease Home
 * What is Crohn’s Disease?
 * What is SKYRIZI?
 * SKYRIZI Results
 * Find a Gastro
 * Resources to Stay on Track
 * About Skyrizi Complete
 * Cost & Savings
 * Sitemap

IMPORTANT SAFETY INFORMATION FOR PATIENTS

 * Important Safety Information
 * Medication Guide
 * Full Prescribing Information

INFORMATION FROM ABBVIE

 * Healthcare Professionals Site
 * Accessibility Statement
 * Contact Us
 * Terms of Use
 * Privacy Notice
 * Cookies Settings
 * Your Privacy Choices



US-SKZG-230203






Leaving AbbVie Web Site

You are leaving the SKYRIZI site and connecting to a site that is not under the
control of AbbVie. AbbVie is not responsible for the contents of any such site
or any further links from such site. AbbVie is providing these links to you only
as a convenience and the inclusion of any link does not imply the endorsement of
the linked site by AbbVie. You should also be aware that the linked site may be
governed by its own set of terms and conditions and privacy policy for which
AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's
endorsement of SKYRIZI.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-SKZ-220373

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site
that is not under the control of AbbVie. AbbVie is not responsible for the
contents of any such site or any further links from such site. AbbVie is
providing these links to you only as a convenience and the inclusion of any link
does not imply the endorsement of the linked site by AbbVie. You should also be
aware that the linked site may be governed by its own set of terms and
conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's
endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are about to enter a site that is for US healthcare professionals only. By
continuing, you certify that you are a healthcare professional and that you wish
to proceed to the healthcare professionals section of this site. Products or
treatments described on this site are available in the US but may not be
available in all other countries.

Iam a licensed healthcare professional and wish to proceed to the healthcare
professionals section of this site.

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site
that is not under the control of AbbVie. AbbVie is not responsible for the
contents of any such site or any further links from such site. AbbVie is
providing these links to you only as a convenience and the inclusion of any link
does not imply the endorsement of the linked site by AbbVie. You should also be
aware that the linked site may be governed by its own set of terms and
conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's
endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site
that is not under the control of AbbVie. AbbVie is not responsible for the
contents of any such site or any further links from such site. AbbVie is
providing these links to you only as a convenience and the inclusion of any link
does not imply the endorsement of the linked site by AbbVie. You should also be
aware that the linked site may be governed by its own set of terms and
conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's
endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site
that is not under the control of AbbVie. AbbVie is not responsible for the
contents of any such site or any further links from such site. AbbVie is
providing these links to you only as a convenience and the inclusion of any link
does not imply the endorsement of the linked site by AbbVie. You should also be
aware that the linked site may be governed by its own set of terms and
conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's
endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090



Leaving AbbVie Web Site

You are leaving the SKYRIZI site and connecting to a site that is not under the
control of AbbVie. AbbVie is not responsible for the contents of any such site
or any further links from such site. AbbVie is providing these links to you only
as a convenience and the inclusion of any link does not imply the endorsement of
the linked site by AbbVie. You should also be aware that the linked site may be
governed by its own set of terms and conditions and privacy policy for which
AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's
endorsement of SKYRIZI.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-SKZ-220373

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site
that is not under the control of AbbVie. AbbVie is not responsible for the
contents of any such site or any further links from such site. AbbVie is
providing these links to you only as a convenience and the inclusion of any link
does not imply the endorsement of the linked site by AbbVie. You should also be
aware that the linked site may be governed by its own set of terms and
conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's
endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site
that is not under the control of AbbVie. AbbVie is not responsible for the
contents of any such site or any further links from such site. AbbVie is
providing these links to you only as a convenience and the inclusion of any link
does not imply the endorsement of the linked site by AbbVie. You should also be
aware that the linked site may be governed by its own set of terms and
conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's
endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Important Updates to the Medication Guide for
SKYRIZI® (risankizumab-rzaa) injection, for subcutaneous use

On January 21, 2022, the SKYRIZI (risankizumab-rzaa) Prescribing Information and
Medication Guide were updated to include new information about serious allergic
reactions. 

The following describes the recent changes to the SKYRIZI Medication Guide.
Please refer to the full Prescribing Information and Medication Guide for
additional safety information.

The following serious side effects were added to the section “What is the most
important information I should know about SKYRIZI?”

SKYRIZI may cause serious side effects, including: 

Serious allergic reactions. Stop using SKYRIZI and get emergency medical help
right away if you get any of the following symptoms of a serious allergic
reaction:

 * fainting, dizziness, feeling lightheaded (low blood pressure)
 * swelling of your face, eyelids, lips, mouth, tongue, or throat
 * trouble breathing or throat tightness
 * chest tightness
 * skin rash, hives
 * itching

Who should not use SKYRIZI?

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the
ingredients in SKYRIZI. See the end of the Medication Guide for a complete list
of ingredients in SKYRIZI here.

This is not a complete list of all the changes made to the Prescribing
Information and Medication Guide for SKYRIZI. Please refer to the full
Prescribing Information and Medication Guide for additional safety information.

INDICATIONS1

SKYRIZI is a prescription medicine used to treat adults: 

• with moderate to severe plaque psoriasis who may benefit from taking
injections or pills (systemic therapy) or treatment using ultraviolet or UV
light (phototherapy). 

• with active psoriatic arthritis (PsA).

Important Safety Information1

What is the most important information I should know about SKYRIZI®
(risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects,
including:

Serious allergic reactions:

• Stop using SKYRIZI and get emergency medical help right away if you get any of
the following symptoms of a serious allergic reaction:

− fainting, dizziness, feeling lightheaded (low blood pressure)

− swelling of your face, eyelids, lips, mouth, tongue, or throat

− trouble breathing or throat tightness

− chest tightness

− skin rash, hives

− itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may
increase your risk of infections. Your healthcare provider should check you for
infections and tuberculosis (TB) before starting treatment with SKYRIZI and may
treat you for TB before you begin treatment with SKYRIZI if you have a history
of TB or have active TB. Your healthcare provider should watch you closely for
signs and symptoms of TB during and after treatment with SKYRIZI.

• Tell your healthcare provider right away if you have an infection or have
symptoms of an infection, including:

− fever, sweats, or chills

− cough

− shortness of breath

− blood in your mucus (phlegm)

− muscle aches

− warm, red, or painful skin or sores on your body different from your psoriasis

− weight loss

− diarrhea or stomach pain

− burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the
ingredients in SKYRIZI.

Before using SKYRIZI, tell your healthcare provider about all of your medical
conditions, including if you:

• have any of the conditions or symptoms listed in the section “What is the most
important information I should know about SKYRIZI?”

• have an infection that does not go away or that keeps coming back.

• have TB or have been in close contact with someone with TB.

• have recently received or are scheduled to receive an immunization (vaccine).
Medications that interact with the immune system may increase your risk of
getting an infection after receiving live vaccines. You should avoid receiving
live vaccines right before, during, or right after treatment with SKYRIZI. Tell
your healthcare provider that you are taking SKYRIZI before receiving a vaccine.

• are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm
your unborn baby.

• are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes
into your breast milk.

Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See “What is the most important
information I should know about SKYRIZI?”

The most common side effects of SKYRIZI include upper respiratory infections,
feeling tired, fungal skin infections, headache, and injection site reactions.

These are not all the possible side effects of SKYRIZI. Call your doctor for
medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to
help. Visit AbbVie.com/myAbbVieAssist to learn more.

Please see accompanying full Prescribing Information or visit
www.rxabbvie.com/pdf/skyrizi_pi.pdf.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
©2022 AbbVie. All rights reserved. US-SKZD-220015 January 2022

US-SKZ-220001

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site
that is not under the control of AbbVie. AbbVie is not responsible for the
contents of any such site or any further links from such site. AbbVie is
providing these links to you only as a convenience and the inclusion of any link
does not imply the endorsement of the linked site by AbbVie. You should also be
aware that the linked site may be governed by its own set of terms and
conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's
endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090


USE

SKYRIZI is a prescription medicine used to treat moderate to severe Crohn's
disease in adults.


IMPORTANT SAFETY INFORMATION

SKYRIZI is a prescription medicine that may cause serious side effects,
including:

Serious allergic reactions: Stop using SKYRIZI and get emergency medical help
right away if you get any of the following symptoms of a serious allergic
reaction:

• fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of
your face, eyelids, lips, mouth, tongue, or throat • trouble breathing or throat
tightness • chest tightness • skin rash, hives • itching

Infections: SKYRIZI may lower the ability of your immune system to fight
infections and may increase


IMPORTANT SAFETY INFORMATION

SKYRIZI is a prescription medicine that may cause serious side effects,
including:

Serious allergic reactions: Stop using SKYRIZI and get emergency medical help
right away if you get any of the following symptoms of a serious allergic
reaction:

• fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of
your face, eyelids, lips, mouth, tongue, or throat • trouble breathing or throat
tightness • chest tightness • skin rash, hives • itching

Infections: SKYRIZI may lower the ability of your


USE

SKYRIZI is a prescription medicine used to treat moderate to severe Crohn's
disease in adults.


IMPORTANT SAFETY INFORMATION

SKYRIZI is a prescription medicine that may cause serious side effects,
including:

Serious allergic reactions: Stop using SKYRIZI and get emergency medical help
right away if you get any of the following symptoms of a serious allergic
reaction:

• fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of
your face, eyelids, lips, mouth, tongue, or throat • trouble breathing or throat
tightness • chest tightness • skin rash, hives • itching

Infections: SKYRIZI may lower the ability of your immune system to fight
infections and may increase


IMPORTANT SAFETY INFORMATION

SKYRIZI is a prescription medicine that may cause serious side effects,
including:

Serious allergic reactions: Stop using SKYRIZI and get emergency medical help
right away if you get any of the following symptoms of a serious allergic
reaction:

• fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of
your face, eyelids, lips, mouth, tongue, or throat • trouble breathing or throat
tightness • chest tightness • skin rash, hives • itching

Infections: SKYRIZI may lower the ability of your


USE

SKYRIZI is a prescription medicine used to treat moderate to severe Crohn's
disease in adults.


IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT SKYRIZI®
(RISANKIZUMAB-RZAA)?

SKYRIZI IS A PRESCRIPTION MEDICINE THAT MAY CAUSE SERIOUS SIDE EFFECTS,
INCLUDING:

SERIOUS ALLERGIC REACTIONS:

 * Stop using SKYRIZI and get emergency medical help right away if you get any
   of the following symptoms of a serious allergic reaction:
   * - fainting, dizziness, feeling lightheaded
     (low blood pressure)
   * - swelling of your face, eyelids, lips, mouth,
     tongue, or throat
   * - trouble breathing or throat tightness
   * - chest tightness
   * - skin rash, hives
   * - itching

INFECTIONS:

SKYRIZI may lower the ability of your immune system to fight infections and may
increase your risk of infections. Your healthcare provider should check you for
infections and tuberculosis (TB) before starting treatment with SKYRIZI and may
treat you for TB before you begin treatment with SKYRIZI if you have a history
of TB or have active TB. Your healthcare provider should watch you closely for
signs and symptoms of TB during and after treatment with SKYRIZI.

 * Tell your healthcare provider right away if you have an infection or have
   symptoms of an infection, including:
   * - fever, sweats, or chills
   * - cough
   * - shortness of breath
   * - blood in your mucus (phlegm)
   * - muscle aches
   * - warm, red, or painful skin
     or sores on your body different from your psoriasis
   * - weight loss
   * - diarrhea or stomach pain
   * - burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the
ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a
complete list of ingredients.

BEFORE USING SKYRIZI, TELL YOUR HEALTHCARE PROVIDER ABOUT ALL OF YOUR MEDICAL
CONDITIONS, INCLUDING IF YOU:

 * have any of the conditions or symptoms listed in the section "What is the
   most important information I should know about SKYRIZI?"
 * have an infection that does not go away or that keeps coming back.
 * have TB or have been in close contact with someone with TB.
 * have recently received or are scheduled to receive an immunization (vaccine).
   Medicines that interact with the immune system may increase your risk of
   getting an infection after receiving live vaccines. You should avoid
   receiving live vaccines right before, during, or right after treatment with
   SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before
   receiving a vaccine.
 * are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm
   your unborn baby.
 * are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes
   into your breast milk.
 * become pregnant while taking SKYRIZI. You are encouraged to enroll in the
   Pregnancy Registry, which is used to collect information about the health of
   you and your baby. Talk with your healthcare provider or call 1-877-302-2161
   to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important
information I should know about SKYRIZI?"

Liver problems in Crohn's disease: A person with Crohn's disease who received
SKYRIZI through a vein in the arm developed changes in liver blood tests with a
rash that led to hospitalization. Your healthcare provider will do blood tests
to check your liver before, during, and up to 12 weeks of treatment and may stop
treatment with SKYRIZI if you develop liver problems. Tell your healthcare
provider right away if you notice any of the following symptoms: unexplained
rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of
appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn’s disease
include: upper respiratory infections, headache, joint pain, stomach (abdominal)
pain, injection site reactions, low red blood cells (anemia), fever, back pain,
and urinary tract infection.

The most common side effects of SKYRIZI in people treated for plaque psoriasis
and psoriatic arthritis include: upper respiratory infections, headache, feeling
tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for
medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL
vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose
prefilled cartridge with on-body injector.

USES

SKYRIZI is a prescription medicine used to treat adults with:

 * moderate to severe plaque psoriasis who may benefit from taking injections or
   pills (systemic therapy) or treatment using ultraviolet or UV light
   (phototherapy).
 * active psoriatic arthritis (PsA).
 * moderate to severe Crohn's disease.

US-SKZ-220579

AbbVie may use and disclose online usage data about you collected automatically
through online tracking technologies such as cookies, pixels, and web beacons
(collectively, “cookies”). We use this data for multiple purposes, including for
online targeted advertising (advertisements based on your interests inferred
from your activity across other unaffiliated sites and services) and website
analytics purposes, as well as to personalize content, save your preferences,
provide social media features, and track the site’s performance, as further
described in the"Cookies and similar tracking and data collection technologies"
section of our Privacy Notice. We retain this data for as long as necessary to
fulfill these purposes or as needed to comply with our record retention
obligations. We do not sell your data, but we may disclose it to our marketing
and advertising partners for purposes of online targeted advertising or for
website analytics purposes. To opt out of the use or disclosure of your
cookie-based personal data for online targeted advertising or for website
analytics purposes, or to otherwise manage your preferences, please click on
Cookie Settings below. For additional information on the categories of data we
collect, the purposes for their collection, disclosures to third parties, and
data retention, please visit ourPrivacy Notice.


Cookies Settings



PRIVACY PREFERENCE CENTER

You can choose not to allow some types of cookies. Click on the different
category headings to find out more and change our default settings. However,
blocking some types of cookies may impact your experience of the site and the
services we are able to offer.

Depending on the jurisdiction where you live, you may have the right to opt out
of the use and disclosure of your personal data for purposes of online targeted
advertising (advertisements based on your interests inferred from your activity
across other unaffiliated sites and services) or website analytics (to
understand website usage behavior and receive website analytics). To opt out of
the use and disclosure of your cookie-based personal data for these purposes,
you can toggle off “Functional” (for website analytics) and/or “Advertising”
(for online targeted advertising) below.

To opt out of the use and disclosure of your non-cookie-based information for
online targeted advertising purposes, please also click"Your Privacy Choices" on
our website.

Note that if we recognize your Global Privacy Control (GPC) as enabled, our
policy is to opt you out of the use or disclosure of your cookie-based personal
data for online targeted advertising and website analytics purposes for the
browser or device on which you have GPC enabled. However, unless you are logged
in to an AbbVie account that has the capability to link the personal data we
have about you to your browser or device, we cannot apply your GPC opt-out
request to your non-cookie based personal data because the connection between
your browser or device is not known to us. Thus, if you have GPC enabled, please
click"Your Privacy Choices" to opt out of the disclosure of your non-cookie
based personal data for these purposes.


MANAGE CONSENT PREFERENCES

REQUIRED COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They may be set by us or by third party providers whose
services we have added to our pages. They are usually only set in response to
actions made by you which amount to a request for services, such as setting your
privacy preferences, logging in or filling in forms. You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work.

View Vendor Details‎

FUNCTIONAL COOKIES

Functional Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They may be set by us or by third party
providers whose services we have added to our pages. They help us to know which
pages are the most and least popular and see how visitors move around the site.

View Vendor Details‎

ADVERTISING COOKIES

Advertising Cookies

These cookies may be set through our site by our advertising partners to build a
profile of your interests and show you relevant adverts on other sites. They do
not store directly personal information but are based on uniquely identifying
your browser and internet device. If you do not allow these cookies, you will
experience less targeted advertising, but you will still receive online
advertising.

View Vendor Details‎
Back Button


PERFORMANCE COOKIES



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

 * 
   
   View Cookies
   
    * Name
      cookie name

Confirm My Choices